secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001193125-24-237869
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave achieves first-ever therapeutic RNA editing in humans in RestorAATion-2 trial of WVE-006
--------------------------------------------------------------------------------

- Single 200 mg dose in first two Pi*ZZ patients produced mean total AAT ~11 µM at day 15, with edited M-AAT >60% of total.
- Wild-type M-AAT reached mean 6.9 µM at day 15, consistent with MZ genotype with low AATD risk.
- WVE-006 well-tolerated; all adverse events mild/moderate, no SAEs; multidose data expected 2025.
- Wave eligible for up to $525M milestones + royalties from GSK; Research Day Oct 30 to show pipeline.
- AATD affects ~200,000 in US/EU; current therapy limited to weekly IV augmentation (>$1.4B sales); no approved liver disease therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524237869/0001193125-24-237869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524237869/d890226d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer